Conogenetix

selectION Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative peptide therapies for autoimmune diseases and targeted cancer indications by specifically targeting autoreactive chronically activated T cells. The company utilizes a unique technology platform that enables the systematic optimization of peptide blockers for ion channels, aiming to enhance drug efficacy and safety profiles.

With a robust team led by experienced executives from the biotechnology and life sciences sectors, selectION is well-positioned to advance its drug development pipeline, which includes promising clinical trials for conditions such as psoriasis vulgaris and atopic dermatitis. The company is supported by notable investors, including SDL Ventures and Global Source Ventures, and has a subsidiary in Martinsried, Germany.

Generated from the website